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Abstract
Background and Aims: Acute and acute on chronic liver fail-
ure are life-threatening conditions, and bridging to trans-
plantation is complicated by a paucity of suitable organs for 
children. While different modalities of extracorporeal liver 
support exist, their use in children is complicated by a large 
extracorporeal volume, and data on their use in children is 
limited. The aim of this analysis was to investigate the effi-
cacy and safety of single-pass albumin dialysis (SPAD) in chil-
dren with liver failure. Methods: Retrospective medical chart 
review of pediatric patients with liver failure treated with 
SPAD. The decrease in hepatic encephalopathy (HE) and the 
serum levels of bilirubin and ammonia were measured to de-
termine efficacy. Adverse events were documented to assess 
safety. Results: Nineteen pediatric patients with a median 
age of 25.5 months and a median body weight of 11.9 kg 
were treated with SPAD between January 2011 and March 
2018. Total bilirubin (p < 0.001) and ammonia (p = 0.02) sig-
nificantly decreased after treatment with SPAD. As clinical 
outcome parameter, HE significantly improved (p = 0.001). 
Twelve patients were bridged successfully to liver transplan-
tation. In all patients, 71 SPAD sessions were run. Clotting in 
the dialysis circuit was observed in 49% of all sessions. Hepa-
rin and citrate were used for anticoagulation and were sig-
nificantly superior to dialysis without any anticoagulation 
(p = 0.03). Transfusion of packed blood cells (57%) and cat-
echolamine therapy (49%) were frequently necessary. Con-
clusions: Treatment with SPAD was effective in detoxifica-
tion, as measured by significant improvement of HE and 
clearance from surrogate laboratory parameters.
© 2019 S. Karger AG, Basel
Introduction
Acute and chronic liver failures are life-threatening 
conditions. Liver transplantation (LTX) has become the 
standard therapy for end-stage liver failure in children 
with 5-year survival rates of 85% [1]. However, acute liv-
er failure (ALF) may be reversible and the availability of 
suitable organs is limited. Therefore, strategies of extra-
corporeal liver support have been developed to bridge to 
recovery or transplantation. The rationale of such extra-
corporeal liver support systems is to reduce endogenous 
water-soluble (e.g., ammonia) as well as protein-bound 





thereby attenuate endotoxinemia and hepatic encepha-
lopathy (HE) [2–5]. 
Water-soluble substances can be effectively removed 
by continuous venovenous hemodiafiltration (CVVHDF) 
[6]. In contrast, protein-bound substances cannot be ef-
fectively eliminated by conventional dialysis techniques 
such as CVVDHF. They need a comparable acceptor on 
the opposite side of the membrane, that is, in the dialysate 
to be eliminated from the blood. To overcome this prob-
lem, albumin is added as a scavenger in the dialysate bath. 
Single-pass albumin dialysis (SPAD) uses a dialysis 
machine capable of CVVHDF. Blood flows through a 
high-flux dialysis filter, and the dialysate contains a vari-
able concentration of human albumin [7].
Our aim was to evaluate the performance of SPAD in 
clinical practice in a representative cohort of pediatric pa-
tients with liver failure. We hypothesize that SPAD effec-
tively removes water-soluble and protein-bound toxins 
represented by ammonia and bilirubin, respectively, as 
surrogate parameters and improves HE as clinical end-
point. As SPAD is used in critically ill children with pos-
sible bleeding disorders and hemodynamic instability, we 
were especially interested in analyzing adverse events 
with a particular focus on the choice of anticoagulant 
 applied. 
Patients and Methods
All patients with ALF or acute on chronic liver failure who were 
treated with SPAD on our pediatric intensive care unit from 
 January 2011 until March 2018 were included in the study. The 
study was performed in accordance with federal and state laws and 
recommendations of the local data safety office. The Institutional 
Review Board of Charité-Universitätsmedizin Berlin waived the 
need for approval due to the retrospective nature of the study.
Clinical and laboratory data were extracted from patients’ re-
cords. These included age, gender, body weight, and diagnosis as 
well as grade of HE according to the West Haven classification [8]. 
Laboratory data included bilirubin, ammonia, creatinine, and in-
ternational normalized ratio. Furthermore, the “model of end-
stage liver disease” score and “pediatric end-stage liver disease” 
score for children below the age of 12 years were calculated [9, 10]. 
Laboratory data were collected at least once per day. Clinical 
data, especially grade of HE, were assessed once per shift, usually 
3 times per day. 
SPAD Setting
Indication for the initiation of SPAD was at least one of the fol-
lowing criteria: HE (grade ≥2), elevated bilirubin (> 400 µmol/L), 
hepatorenal syndrome according to the definition of Bozanich and 
Kwo [11] or elevated ammonia (> 200 µmol/L). A central venous 
double-lumen catheter was placed in the jugular vein, subclavian 
vein or femoral vein. The minimum catheter size was 6.5 French.
SPAD was performed as a post-dilution CVVHDF with Plas-
auto Sigma (Asahi Kasei Kuraray Medical Co., Ltd., Chiyoda Ku, 
Japan) using an Ultraflux EMiC2 dialyzer (Ultraflux® dialyzer, 
steam-sterilized, covering 1.8 m2 surface area, Fresenius Polysul-
fone® membrane, Fresenius Medical Care GmbH, Bad Homburg, 
Germany). Dialyzer (130 mL) plus dialysis circuit (69 mL for chil-
dren and adolescents and 47 mL for children with a body weight 
below 20 kg) were partially filled with packed red blood cells in case 
of hemodynamic instability. Blood flow rates between 3 and 5 mL/
kg * min were achieved. As dialysis solution, either CiCa Dialysate 
K2 (Fresenius Medical Care GmbH, Bad Homburg, Germany) for 
citrate anticoagulation or Accusol 35 (Baxter Healthcare Ltd., 
Thetford, UK) for heparin anticoagulation were used. A 3–5% al-
bumin solution was produced online using one additional roller 
pump for human albumin 20% (Baxter Healthcare Ltd., Thetford, 
UK) which was then mixed via Y connector with the CiCa Dialy-
sate K2 or Accusol 35 dialysis solution, as described previously by 
our group [7]. This albumin solution for hemodialysis was set con-
tinuously at flow rates of 20–40 mL/kg * h. The continuous veno-
venous hemofiltration was performed with Accusol 35 or CiCa K2 
dialysis solution as substitution solution. 
Anticoagulation was administered either by continuous hepa-
rin or regional citrate anticoagulation (RCA). The choice was 
made individually by the treating physician before starting SPAD 
treatment. There was no treatment algorithm for the choice and 
dosage of the anticoagulant. Patients that were considered subjec-
tively to have a high risk of bleeding were started with RCA or 
without any anticoagulation. Patients with citrate accumulation, 
indicated by an increased total/ionized calcium ratio > 2.5 or un-
controllable alkalosis or acidosis, were switched to heparin antico-
agulation. 
Outcome Analysis
Effectiveness of SPAD was investigated by comparison of clin-
ical (HE) and laboratory data (ammonia, bilirubin) within 24 h 
prior and after initiation of SPAD. The final outcome (transplanta-
tion, survival) was registered. 
The duration of dialysis sessions under different modes of an-
ticoagulation, reasons for interruptions as well as complications 
were recorded. These included blood transfusions, need for vaso-
active medication, allergic reactions, and bleeding complications. 
Bleeding was classified as “life-threatening” following criteria 
proposed for children with hemorrhagic complications in dialysis-
dependent acute kidney failure [12]. In our setting, a hemorrhagic 
complication was defined as “life-threatening” (1) when blood he-
moglobin fell by > 2 g/dL/6 h or required transfusion of > 20 mL 
packed red cells per kilogram body weight in 24 h, (2) when bleed-
ing involved vulnerable locations, for example, brain, pericardium, 
lung or (3) when bleeding significantly affected vital parameters 
requiring an altered use of catecholamines. Non-life-threatening 
episodes included bleeding from catheter insertion site, mucosal 
bleeding (nose, mouth) without need for intervention, tracheal 
bleeding without respiratory decompensation, gastrointestinal 
bleeding without need for intervention, skin bleeding, and hema-
turia without vesical tamponade.
Statistical Analysis
Microsoft Excel (2013) and GraphPad Prism (7.04; GraphPad 
Software, La Jolla, CA, USA) were used for data collection and sta-
tistical analysis. Normality of variables was tested by Shapiro-Wilk 
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normality test. Paired t test and Wilcoxon matched-pairs signed 
rank test were used to compare variables. The association of body 
weight with the duration of dialysis sessions was analyzed using 
Pearson correlation and visualized using a regression line in a scat-
ter plot. p values < 0.05 were considered as statistically significant. 
Data are shown as mean ± SD or median (interquartile range 
[IQR]). 
Results
Nineteen pediatric patients (7 girls, 12 boys) with ALF 
or acute on chronic liver failure were treated with SPAD. 
Patient demographic characteristics are shown in Table 1 
and clinical and laboratory characteristics before initia-
tion of SPAD are shown in online supplementary Table 1 
(for all online suppl. material, see www.karger.com/
doi/10.1159/000502938; supplemental data available 
upon request at the corresponding author). The median 
age of the patients was 25.5 (152.8) months and the me-
dian body weight was 11.85 (39.7) kg. The most common 
diagnosis leading to the prescription of SPAD was ALF of 
unknown origin in 7 cases, followed by gestational allo-
immune liver disease in 3 cases.
In 3 patients, SPAD treatment was discontinued for 
>48 h due to transient recovery of liver function (patients 
1 and 15) or transplantation (patient 18) and restarted 
when liver function deteriorated again. 
SPAD Settings
Data of dialysis modalities are shown in Table 2. The 
median duration of SPAD was 65.5 h (IQR 76.5; minimum 
5; maximum 369). In total, 71 SPAD sessions were per-
formed. The median session time was 21.5 (IQR 30.5) h. 
The median blood flow was 3.8 (IQR 1.7) mL/kg * min, 
median substitution fluid flow was 31.5 (IQR 21.25) mL/
kg * h, and median dialysate flow was 26 (IQR 17.25) mL/
kg * h with a median of 4% concentration of albumin. 
Only 17/71 sessions (23.4%) were longer than 36 h, 
while max. 48 hours were aspired for scheduled filter and 
system replacement. The patients’ weights had no influ-
ence on session time (r2 = 0.02; p = 0.28; Fig. 1a). 
There was a significant correlation between anticoagu-
lation and the duration of dialysis sessions (Fig. 1b). Cy-
cles in which SPAD was conducted without anticoagula-
tion (n = 7) had significant shorter cycle duration than 
patients with heparin (n = 41; p = 0.03) or RCA (n = 23; 
Table 1. Demographic characteristics and clinical outcome of patients treated with SPAD
Patient Age, months Weight, kg Gender Outcome Cause of death
1a 25 11 Male Recovery
1b 26 12 Male # Sepsis
2 205 75 Male LTX
3 205 62 Female # ARDS
4 1 4.2 Male Recovery
5 1 5.4 Male LTX, # MOF
6 24 9.0 Male Re-LTX
7 205 75 Female LTX
8 199 52 Male LTX
9 2 3.5 Female LTX
10 162 80 Female LTX
11 22 12 Male LTX
12 39 15 Male LTX
13 0.5 2.6 Male # MOF
14 6 6 Male # CE
15a 58 27 Female Recovery
15b 58 27 Female # Sepsis
16 24 10 Female LTX
17 4 6.5 Male # MOF
18a 155 44 Female LTX
18b 155 44 Female Recovery
19 4 7.6 Female LTX, # MOF
SPAD, single-pass albumin dialysis; #, death; LTX, liver transplantation; ARDS, acute respiratory distress 





Table 2. Dialysis data of all patients treated with SPAD






c Albumin, % Anticoagulant
1a 91 4.8 22 31 3 Heparin
1b 81.5 4.3 25 24 3 Heparin
2 33 3.2 35 35 3 Citrate
3 120.5 2.2 20 31 5 Heparin
4 39.5 4.8 20 30 5 Heparin
5 23.5 2.8 18 24 5 Heparin
6 368.75 3.4 24 18 4 Heparin
7 46.75 4.5 32 32 5 */heparin
8 91.5 4.1 29 19 4 */heparin
9 18.5 7.1 21 29 4 Citrate
10 120.5 2.8 21 17 3 Heparin
11 70 3.3 15 20 5 Citrate
12 74.5 3.5 30 23 4 Citrate
13 172 6 38 39 4 Citrate
14 61 4.4 27 43 4 Citrate
15a 18.25 2.8 52 56 3 Citrate
15b 8.25 2.8 37 44 4 Citrate
16 128 6.1 53 53 4 Citrate
17 7 5.2 46 107 4 Heparin
18a 78.25 3.2 20 45 4 */heparin
18b 11.5 3.2 20 45 4 *
19 50.5 4.6 53 51 3 Heparin
* No anticoagulation.
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Fig. 1. Influence of body weight and anticoagulation on SPAD du-
ration. a Association of duration of each single session and pa-
tient’s body weight. There was no significant association between 
both parameters analyzed by Pearson correlation and visualized by 
linear regression. b Influence of anticoagulation on the duration of 
SPAD sessions. Patients without any anticoagulation had signifi-
cant lower session times than patients with heparin or citrate anti-
coagulation. Bars indicate median values, whiskers indicate IQR. 
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p = 0.03). The most common cause for the termination 
was clotting in the dialysis circuit (49%). About 14% of 
sessions were discontinued for scheduled filter or dialysis 
machine change and 13% due to LTX.
Efficacy of SPAD
We observed a significant decrease of surrogate labo-
ratory markers and clinical grade of encephalopathy 
(Fig. 2). Ammonia levels decreased significantly during 
therapy (median decrease 36.5 µmol/L, p = 0.02). Biliru-
bin decreased significantly in all patients (median de-
crease 193 µmol/L; p < 0.001). There were no significant 
differences in the bilirubin clearance according to the al-
bumin concentration in the dialysate bath, which ranged 
between 3 and 5% (online suppl. Fig.  1, Supplemental 
data available upon request to the corresponding author). 
HE improved or remained stable in all patients during 
SPAD (median improvement 1.0, mean improvement 
0.84; p = 0.01). 
Outcome
Clinical outcome is shown in Table 1. In our, cohort 8 
of 19 patients deceased. Two patients deceased after LTX, 
6 patients while waiting for a graft, having a contraindica-
tion for transplantation or being switched to palliative 
care. Twelve of 19 patients (63%) were bridged to LTX. 
After LTX, 1 patient underwent another session of SPAD 
due to insufficient graft function; after 12 h, SPAD was 
discontinued. Two patients died 3 weeks and 3 months 
after LTX, respectively. All other patients had sufficient 
liver function on discharge from our pediatric intensive 
care unit. Three patients displayed temporary recovery of 
liver function during SPAD. The first (patient 1a) had 
neuroblastoma-amplified sequence mutation (OMIM 
608025) with acute onset of liver failure during a febrile 
infection and recovered after 46 h of SPAD. He deceased 
during a second episode of liver failure. A second child 
(patient 4) with gestational alloimmune liver disease re-
covered after 40 h of SPAD; the third child (patient 15a) 
recovered temporarily and albumin dialysis was discon-
tinued before liver function deteriorated again. Eventu-
ally, the child deceased as transplantation was not possi-
ble due to metastatic malignant disease. 
Complications
There were no allergic reactions during SPAD. Most 
common complications were non-life-threatening bleed-
ings. During SPAD, bleedings in the ear/nose/throat area 
(n = 20), catheter insertion site (n = 18), gastrointestinal 
bleeding (n = 9), hematuria (n = 5), and skin bleedings 
(n = 6) were reported. One patient suffered from a life-
threatening pulmonary hemorrhage with secondary car-
diorespiratory decompensation leading to the discontin-
uation of SPAD. Inappropriately rapid re-transfusion of 
blood in a small child (4.2 kg) at the end of dialysis was 
identified as the reason for this complication. 
Two out of 10 patients, in who RCA was initiated, were 
switched to heparin anticoagulation due to citrate accumu-
lation. There were no differences in the frequency of minor 
hemorrhages between the heparin and the RCA groups.
No patient died due to a direct complication of SPAD. 
In 53/71 sessions (75%) packed blood cells were substi-
tuted and in 35/71 sessions (49%) catecholamine therapy 












































Pre SPAD Post SPAD
p = 0.01
ba c
Fig. 2. Efficacy of SPAD. Efficacy of SPAD according to elimination of ammonium (a), bilirubin (b), and improvement of HE (c). Bars 
indicate median and interquartile range. p value indicates significance of difference before and after SPAD. SPAD, single-pass albumin 






In this analysis, we assessed the performance of SPAD 
under clinical conditions in pediatric intensive care treat-
ment of liver failure. SPAD is administered to patients 
with liver failure with the intention to bridge to trans-
plantation or hepatic recovery, although we know little 
about its benefits. To date, this is the largest series of chil-
dren treated with SPAD for liver failure. With 13/19 pa-
tients (68%) with a body weight of 15 kg or less, our data 
reflect the unique features of a pediatric cohort. 
We are well aware of the fact that our retrospective 
evaluation without control group cannot answer the most 
meaningful clinical outcomes such as a possible benefit in 
survival, mechanical ventilation or vasopressor support 
in comparison to a cohort undergoing standard medical 
treatment without SPAD. However, we demonstrate that 
SPAD significantly eliminates water-soluble compounds, 
such as ammonia, and protein-bound substances, such as 
bilirubin. However, the most important clinical benefit is 
the significant improvement of HE. 
The comparison of our results to available data is com-
plicated by the fact that various modalities of extracorpo-
real liver support exist and most data are derived from 
adult patients. Hence, a direct comparison is impossible. 
A commercially available and extensively studied system 
using albumin dialysis is the molecular adsorbents recir-
culating system (MARS Baxter, Stockholm, Sweden, 
1996) [13]. To minimize extracorporeal circulation, a vol-
ume-adapted pediatric MARS system (MARSmini) has 
been developed for use in children [14, 15]. Different ap-
proaches use a combination of plasmapheresis and he-
modialysis, performed simultaneously with a plasma sep-
arator and a high-flux filter configured serially in children 
with ALF [15, 16]. 
In children, most reports on extracorporeal liver sup-
port systems in children focus on MARS [15, 17–20]. 
Only few reports exist about the use of SPAD as a detoxi-
fication device, especially in Wilson’s disease and drug 
intoxication [7, 21, 22]. 
Regarding the clinical efficacy of SPAD, we could cor-
roborate the reduction of HE reported by our study group 
in a previous case series [7]. This effect is comparable to 
MARS whereas there is no comparable data on combined 
plasma exchange and hemodialysis [7, 16, 23, 24]. 
Respecting the improvement of laboratory surrogate 
parameters, the effective elimination of bilirubin with 
SPAD in our cohort seems to be comparable with results 
from children treated with MARS and with combined 
plasma exchange and hemodialysis [15, 16, 19]. 
In contrast to our data, a meta-analysis on albumin 
dialysis failed to demonstrate a significant decrease in 
ammonia [25]. As ammonia is similar to urea in terms of 
diffusive clearance [6], this could be explained by an in-
sufficient dose of hemodialysis. 
Currently, there is only one open randomized trial 
demonstrating a potential survival benefit of high-vol-
ume plasma exchange in adult patients with acute liver 
disease [26]. For MARS, despite the positive effects on 
short-term toxin removal and HE, a survival benefit could 
not be demonstrated in adult patients [25, 27]. There is 
no comparable pediatric data. 
Despite the lack of head-to-head comparisons be-
tween SPAD and other liver replacement methods in chil-
dren, we postulate SPAD as a possibly effective treatment 
in children with liver failure. Apart from the versatility, 
there are several theoretical advantages of SPAD in chil-
dren in comparison to other liver support systems. 
In contrast to MARS and high-volume plasma ex-
change with treatment sessions of up to 8 h, SPAD oper-
ates as a CVVHDF, as used normally in critically ill and 
hemodynamically unstable patients. Hereby, detoxifica-
tion occurs continuously with a lower risk of disequilib-
rium through excessive and intermittent toxin removal. 
Further, it is a potential advantage of SPAD that blood 
flow rates, duration of therapy, and albumin concentra-
tion can be individually tailored for each patient. Al-
though we still ignore the optimal dose for the individual 
patient, this hypothesis is supported by a meta-analysis 
on albumin dialysis which showed a non-significant 
trend towards risk reduction in mortality only in studies 
with more dialysis sessions [25]. 
A clinically relevant advantage of SPAD is the low ex-
tracorporeal volume allowing the application even in 
small children as shown in our cohort with a median 
weight of 11 kg. The disposal of albumin after single use 
is an apparent disadvantage of the technique. On the con-
trary, there is evidence for a decline of the albumin con-
centration during MARS therapy due to the binding of 
albumin to the adsorbent columns [28]. Furthermore, the 
costs for 24 h SPAD are markedly lower than for a MARS 
system. With our settings (median dialysate flow 26 mL/
kg * h and median albumin concentration 4%), around 
125 mL human albumin 20% are used per kilogram pa-
tient’s weight in 24 h. In addition, in comparison to plas-
ma exchange and hemodialysis, there is less exposure to 
foreign donor blood products, and thereby a reduced risk 
for allergic reactions and HLA sensitization. 
The number of deceased patients raises concern 
whether SPAD is limited in stabilizing and bridging pa-
SPAD in Children with Liver Failure 61Blood Purif 2020;49:55–62
DOI: 10.1159/000502938
tients to transplantation. The only severe complication, 
however, directly associated with SPAD occurred in a 
child with a body weight of 4.2 kg who suffered from pul-
monary hemorrhage. The child recovered without se-
quelae. We expected low blood flow rates in small chil-
dren to lead to a higher risk of clotting. Interestingly, pa-
tients’ weights had no influence on the duration of the 
dialysis sessions and clotting in our cohort. 
We accepted the risk of clotting over the risk of bleed-
ing by starting dialysis without anticoagulation in 6/19 
(32%) patients. No anticoagulation was inferior to hepa-
rin and RCA regarding filter life, whereas no significant 
difference in filter life between RCA and heparin antico-
agulation was observed. Of note, RCA could be safely ad-
ministered in patients with severe liver dysfunction. 
However, our cohort size was too small to evaluate the 
issue of adequate anticoagulation conclusively in patients 
with liver failure.
Major limitations of our observations are the retro-
spective design and the lack of control group. Thus, it is 
impossible to draw robust conclusions on mortality. In-
dications for the treatment might vary between different 
patients. A prospective, protocol-based approach would 
allow better comparisons of patients. The results of this 
analysis outline potentially fruitful areas of future clinical 
research. It is presently unclear which metabolites and 
toxins play a crucial role in ALF. Different substances 
with a possible role in HE like manganese, pro-inflamma-
tory cytokines as well as mercaptans, short-chain fatty ac-
ids, GABA, glutamate and others could be investigated 
prospectively [29, 30]. 
In conclusion, we report about a pediatric cohort with 
liver failure, treated with SPAD. Although a direct com-
parison is impossible, efficacy seemed similar to other re-
ports about extracorporeal liver support in adult patients 
or in children treated with MARS. Regarding document-
ed direct adverse effects of SPAD, the method appeared 
safe. However, further investigations are needed to evalu-
ate the effect on meaningful clinical outcomes, especially 
survival and long-term neurologic sequelae, as well as ap-
propriate and individual dosage. 
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